Heidi Leblanc

3.3k total citations · 2 hit papers
15 papers, 2.5k citations indexed

About

Heidi Leblanc is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Heidi Leblanc has authored 15 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Immunology. Recurrent topics in Heidi Leblanc's work include CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Photosynthetic Processes and Mechanisms (3 papers). Heidi Leblanc is often cited by papers focused on CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Photosynthetic Processes and Mechanisms (3 papers). Heidi Leblanc collaborates with scholars based in United States, Canada and Germany. Heidi Leblanc's co-authors include Avi Ashkenazi, David A. Lawrence, Peter Schow, Eugene Varfolomeev, Frank Kischkel, Sharon Fong, John Morlan, Dominick Sinicropi, Ralph Schwall and Klára Tótpál and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Heidi Leblanc

14 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apo2L/TRAIL and its death and decoy receptors

2003 705 citations Heidi Leblanc, Avi Ashkenazi Cell Death and Differentiation profile →
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

2014 472 citations Changyu Wang, Kent Thudium et al. Cancer Immunology Research profile →

Peers

Countries citing papers authored by Heidi Leblanc

Since Specialization

Citations

This map shows the geographic impact of Heidi Leblanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Leblanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Leblanc more than expected).

Fields of papers citing papers by Heidi Leblanc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Leblanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Leblanc. The network helps show where Heidi Leblanc may publish in the future.

Co-authorship network of co-authors of Heidi Leblanc

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Leblanc. A scholar is included among the top collaborators of Heidi Leblanc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Leblanc. Heidi Leblanc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab 2024 ·Journal for ImmunoTherapy of Cancer ·Ludimila Cavalcante, Sreenivasa R Chandana, Nehal J. Lakhani, Amanda Enstrom, Heidi Leblanc, (unknown), (unknown), Frank Schneider, (unknown), Michael Chisamore, Stanford L. Peng, (unknown), Diwakar Davar	6
2	Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) 2024 ·Journal for ImmunoTherapy of Cancer ·Diwakar Davar, Ludimila Cavalcante, Nehal J. Lakhani, Justin C. Moser, (unknown), Meredith McKean, Mark Voskoboynik, Rachel E. Sanborn, Jaspreet Singh Grewal, (unknown), Amita Patnaik, Justin F. Gainor, Mario Sznol, Amanda Enstrom, (unknown), Heidi Leblanc, (unknown), Michael Chisamore, Stanford L. Peng, (unknown)	3
3	605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models 2020 ·SHILAP Revista de lepidopterología ·Heidi Leblanc, Cecelia I. Pearson, Justin A. Kenkel, Lisa K. Blum, Po Y. Ho, Angela Luo, Richard Laura, (unknown), (unknown), (unknown), Shelley E. Ackerman, Brian S. Safina, David Dornan, Michael N. Alonso, Marcin Kowanetz	5
4	A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer 2018 ·Clinical Cancer Research ·Paul Ponath, Daniel L. Menezes, Chin Pan, Bing Chen, Miho Oyasu, Debbie Strachan, Heidi Leblanc, Huadong Sun, Xitao Wang, Vangipuram S. Rangan, Shrikant Deshpande, Sandra Cristea, (unknown), Julien Sage, Pina M. Cardarelli	39
5	In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates breakdown → 2014 ·Cancer Immunology Research ·Changyu Wang, Kent Thudium, Minhua Han, Xitao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Wu, Michelle Kuhne, M. S. Srinivasan, Sujata Singh, Susan Wong, Neysa Garner, Heidi Leblanc, Roderick T. Bunch, Diann Blanset, Mark Selby, Alan J. Korman	472
6	A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis 2011 ·Arthritis & Rheumatism ·Michael Yellin, (unknown), Andra Bălănescu, (unknown), Vira Tseluyko, (unknown), Xiaolu Tao, Pina M. Cardarelli, Heidi Leblanc, Geoff Nichol, Codrina Ancuța, Rodica Chirieac, Allison Luo	149
7	Directed mutagenesis and gene fusion analysis of the Rhodobacter capsulatus puc operon 2009 ·Open Collections ·Heidi Leblanc	0
8	The PucC protein of Rhodobacter capsulatus mitigates an inhibitory effect of light-harvesting 2 α and β proteins on light-harvesting complex 1 2007 ·Photosynthesis Research ·Paul R. Jaschke, Heidi Leblanc, Andrew S. Lang, J. Thomas Beatty	10
9	TWEAK Attenuates the Transition from Innate to Adaptive Immunity 2005 ·Cell ·Heather Maecker, Eugene Varfolomeev, Frank Kischkel, David A. Lawrence, Heidi Leblanc, Wyne Lee, Stephen D. Hurst, Dimitry M. Danilenko, Jun Li, Ellen Filvaroff, Becky Yang, Dylan Daniel, Avi Ashkenazi	202
10	Apo2L/TRAIL and its death and decoy receptors breakdown → 2003 ·Cell Death and Differentiation ·Heidi Leblanc, Avi Ashkenazi	705
11	Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax 2002 ·Nature Medicine ·Heidi Leblanc, David A. Lawrence, Eugene Varfolomeev, Klára Tótpál, John Morlan, Peter Schow, Sharon Fong, Ralph Schwall, Dominick Sinicropi, Avi Ashkenazi	431
12	Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8 2001 ·Journal of Biological Chemistry ·Frank Kischkel, David A. Lawrence, Antoine Tinel, Heidi Leblanc, Arvind K. Virmani, Peter Schow, Adi F. Gazdar, John Blenis, David Arnott, Avi Ashkenazi	424
13	The mitotic centromeric protein MEI-S332 and its role in sister-chromatid cohesion 1999 ·Chromosoma ·Heidi Leblanc, (unknown), Jim S. Wu, Terry L. Orr‐Weaver	37
14	Transcript Cleavage, Attenuation, and an Internal Promoter in the Rhodobacter capsulatus puc Operon 1999 ·Journal of Bacteriology ·Heidi Leblanc, Andrew S. Lang, J. Thomas Beatty	11
15	Topological analysis of the Rhodobacter capsulatus PucC protein and effects of C-terminal deletions on light-harvesting complex II 1996 ·Journal of Bacteriology ·Heidi Leblanc, J. Thomas Beatty	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact